Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease

Abstract

IMPORTANCE Monogenic familial hypercholesterolemia (FH) is associated with lifelong elevations in low-density lipoprotein cholesterol (LDL-C) levels and increased risk of atherosclerotic cardiovascular disease (CVD). However, many individuals with hypercholesterolemia have a polygenic rather than a monogenic cause for their condition. It is unclear if a genetic variant for hypercholesterolemia alters the risk of CVD. OBJECTIVES To assess whether a genetic variant for hypercholesterolemia alters the risk of atherosclerotic CVD and to evaluate how this risk compares with that of nongenetic hypercholesterolemia. DESIGN, SETTING, AND PARTICIPANTS In this genetic-association, case-control, cohort study, individuals aged 40 to 69 years were recruited by the UK Biobank from across the United Kingdom between March 13, 2006, and October 1, 2010, and followed up until March 31, 2017. Genotyping array and exome sequencing data from the UK Biobank cohort were used to identify individuals with monogenic (LDLR, APOB, and PCSK9) or polygenic hypercholesterolemia (LDL-C polygenic score >95th percentile based on 223 single-nucleotide variants in the entire cohort). The data were analyzed from July 1, 2019, to December 30, 2019. MAIN OUTCOMES AND MEASURES The study investigated the association of genotype with the risk of coronary and carotid revascularization, myocardial infarction, ischemic stroke, and all-cause mortality among the overall study population and among participants with monogenic FH (n = 277), polygenic hypercholesterolemia (n = 2379), or hypercholesterolemia with undetermined cause (n = 2232) at comparable levels of LDL-C measured at study enrollment. RESULTS For the 48 741 individuals with genotyping array and exome sequencing data, the mean (SD) age was 56.6 (8.0) years, and 54.5% were female (n = 26 541 of 48 741). A monogenic FH variant for hypercholesterolemia was found in 277 individuals (0.57%, 1 in 176 individuals). Participants with monogenic FH were significantly more likely than those without monogenic FH to experience an atherosclerotic CVD event at 55 years or younger (17 of 277 [6.1%] vs 988 of 48 464 [2.0%]; P < .001). Compared with the general population, both monogenic and polygenic hypercholesterolemia were associated with an increased risk of CVD events. Moreover, among individuals with comparable levels of LDL-C, both monogenic (hazardratio,1.93;95%CI,1.34-2.77;P < .001)andpolygenichypercholesterolemia(hazardratio,1.26; 95% CI, 1.03-1.55; P = .03) were significantly associated with an increased risk of CVD events compared with the risk of such events in individuals with hypercholesterolemia without an identified genetic cause. CONCLUSIONS AND RELEVANCE The findings of this study suggest that among individuals with hypercholesterolemia, genetic determinants of LDL-C levels may impose additional risk of CVD. Thus, understanding the possible genetic cause of hypercholesterolemia may provide important prognostic information to treat patients.

Nutrition and Genetics in NAFLD: The Perfect Binomium

“…The minor C allele was found significantly correlated with a strong increase in fasting insulin levels and HOMA-IR in response to high-carbohydrate diet consumption, providing novel information in guiding dietary intervention in diabetic patients. Nonetheless, alterations in PCSK9, another member of the Proprotein Convertase Subtilisin/Kexin family, have been broadly associated with familial hypercholesterolemia [92], severe steatosis [93] and cardiovascular risk [94], as a consequence of its role in the modulation of low-density lipoprotein (LDL) uptake. PCSK9 expression is strongly influenced by nutritional status.…”

ATP-sensitive potassium channels gene polymorphism rs1799858 affects the risk of macro-/micro-vascular arteriosclerotic event in patients with increased low-density lipoprotein cholesterol levels

“…KATP is not only involved in the metabolic regulation of coronary vascular tone (e.g., coronary KATP) but also in mediating oxidative stress (e.g., mitochondrial KATP) [45,46]. ASCVD (e.g., CAD) results from a cross-talk between environmental and genetic factors [47]. Although environmental factors (e.g., high-cholesterol diet) play a role in ASCVD, genetic factors are a major determinant of ASCVD.…”

Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease

“…Furthermore, alterations in PCSK9, another member of the proprotein convertase subtilisin/kexin family, have been broadly associated with familial hypercholesterolemia [156], severe steatosis [157] and cardiovascular risk [158], as a consequence of its role in the modulation of low-density lipoprotein LDL uptake. PCSK9 expression is strongly influenced by nutritional status and its expression impressively decreases in mice after 24 h of fasting.…”